Curative treatment of colorectal peritoneal carcinomatosis: Current status and future trends
|
|
- Maximilian Dickerson
- 6 years ago
- Views:
Transcription
1 Curative treatment of colorectal peritoneal carcinomatosis: Current status and future trends Léon Maggiori, Dominique Elias To cite this version: Léon Maggiori, Dominique Elias. Curative treatment of colorectal peritoneal carcinomatosis: Current status and future trends. EJSO - European Journal of Surgical Oncology, WB Saunders, 2010, 36 (7), pp.599. < /j.ejso >. <hal > HAL Id: hal Submitted on 26 Jun 2011 HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers. L archive ouverte pluridisciplinaire HAL, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.
2 Accepted Manuscript Title: Curative treatment of colorectal peritoneal carcinomatosis: Current status and future trends Authors: Léon Maggiori, Dominique Elias PII: S (10) DOI: /j.ejso Reference: YEJSO 2969 To appear in: European Journal of Surgical Oncology Received Date: 22 February 2010 Accepted Date: 4 May 2010 Please cite this article as: Maggiori Léon, Elias D. Curative treatment of colorectal peritoneal carcinomatosis: Current status and future trends, European Journal of Surgical Oncology (2010), doi: /j.ejso This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
3 Review CURATIVE TREATMENT OF COLORECTAL PERITONEAL CARCINOMATOSIS : CURRENT STATUS AND FUTURE TRENDS Léon Maggiori, MD, Dominique Elias, MD, PhD Department of Surgical Oncology Institut Gustave Roussy Address for correspondence and reprints: Dominique Elias, Département de Chirurgie Générale Oncologique, Institut Gustave Roussy, 39 rue Camille Desmoulins, Villejuif Cédex, France (Tel ; dominique.elias@igr.fr) Titre 1
4 INTRODUCTION Peritoneal dissemination or carcinomatosis from colorectal carcinoma is a form of disease progression which can affect 30 to 40% of patients [1, 2]. Natural history studies show that peritoneal carcinomatosis (PC) is uniformly fatal, with median survival not exceeding 6 months [3]. For more than a decade, as an alternative approach to overcome this disease, a handful of centers have pursued aggressive cytoreductive surgery to resect macroscopic disease as much as possible, combining it with intraperitoneal chemotherapy (initially without and then with hyperthermia), to treat any residual occult disease. The aim of this review is to report the current status of this novel combined treatment, focusing on issues that have been solved and those which continue to pose problem and attempting to foresee future developments. 1) A new therapeutic concept becoming increasingly popular Concept In 1980, Spratt was the first to describe the combination of maximal cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (HIPEC) to treat a recurring peritoneal pseudomyxoma [4], but the main apostle of this method was PH Sugarbaker [5]. The main principles are : treating the macroscopic (visible) malignant peritoneal disease with complete cytoreductive surgery (CCRS), and immediately after, treating the remaining microscopic (non visible) malignant peritoneal disease with HIPEC. It is essential that surgery resects all tumor seeding greater than 1 mm because the chemotherapy bath cannot penetrate tumor seeding beyond 1-2 mm Titre 2
5 in depth [6, 7]. Hyperthermia, in addition to intraperitoneal chemotherapy, has clearly demonstrated its ability to potentiate the penetration and activity of local chemotherapy in cancer cells in vitro, and this role was confirmed in vivo in several studies [8, 9]. Finally, HIPEC must be performed immediately after surgery to avoid peritoneal adhesions in which cancer cells become trapped and could constitute a tumor sanctuary [10, 11]. HIPEC is becoming widespread Publications devoted to HIPEC have increased exponentially between 1994 and To date, approximately five hundred have concerned colorectal PC. At the same time, the number of centers using HIPEC has progressively increased worldwide. In France, it increased from 3 in 1994 to 25 in This reflects the enhanced interest of physicians in this new therapeutic approach. 2) Validated and nonvalidated aspect of this combined treatment Global results This combined treatment (CCRS immediately followed by HIPEC) works, as definitively demonstrated by the randomized study of the Amsterdam group: 105 patients presenting colorectal PC were randomized between surgery + HIPEC (and systemic chemotherapy) versus systemic chemotherapy alone [12]. In that study, 50% of the patients in the experimental arm were ultimately not good candidates for HIPEC because their PC could not be completely surgically resected. In spite of Titre 3
6 this selection bias, the reported median survival was 22 months in the experimental arm versus 13 months in the control group (p=0.032) (figure 1). A more recent retrospective study compared similar patients with resectable PC treated with CCRS and HIPEC to standard systemic chemotherapy: the median survival rate was 63 months in the CCRS + HIPEC group versus 24 months in the systemic chemotherapy group (figure 2) [13]. Complete cytoreductive surgery The impact of the completeness of cytoreductive surgery is very strong in this combined treatment. This is clearly apparent in all studies from experienced as well as less experienced centers. For example, we report in figure 3 the survival rates according to the radicality of surgery in the 523 patients collected by the AFC (Association Française de Chirurgie) registry [14]. This study underlined the strong impact of the completeness of cytoreductive surgery on overall survival: 5 years after surgery, no patient was alive if the size of the remaining tumor nodules after surgery was 2.5 millimeters whereas nearly 30% of the patients were alive if CCRS was possible (p<0.0001). Furthermore, CCRS was identified as an independent prognostic factor for disease-free survival (p=0.05). Hyperthermic Intraperitoneal Chemotherapy The exact effect of HIPEC alone in this package is currently unknown in human beings. Its role is to cure the residual microscopic PC after complete cytoreductive surgery. In a randomized trial in rats, those treated with HIPEC survived longer than those treated with intraperitoneal chemotherapy alone or exclusively with intraperitoneal hyperthermia [8]. Until now, no comparable trial Titre 4
7 has been proposed to patients, but a French randomized multicentric trial (Prodige 7) is ongoing which is comparing HIPEC versus no HIPEC after complete cytoreductive surgery. HIPEC techniques are heterogeneous but their elaboration is highly complex. The combination of drugs can be modified, as can their concentration, but also the composition as well as the volume of the perfusion, the duration, and the temperature. A high number of combinations of these six parameters is possible, and it is not possible to test all of them. Each modification of one of these parameters implies conducting a new pharmacokinetic study. Schematically, there are two main trends worldwide for HIPEC : one uses mitomycin C over min at 41 C with a closed-abdomen technique, and the other uses oxaliplatin (± irinotecan) over min at 43 C with an opened-abdomen technique. In the future, there is a rationale for conducting HIPEC with other drugs and new targeted therapy (without hyperthermia, if monoclonal antibodies are used). 3) What indications and what results in 2010? Indications Indications are based on absolute and relative contraindications. An absolute contraindication for CCRS plus HIPEC is a poor general status, the presence of extra-peritoneal metastases and huge and diffuse PC. Relative contraindications are : a subocclusive syndrome due to more than one digestive stenosis, peritoneal disease progressing under chemotherapy and the presence of more than 3 Titre 5
8 resectable liver metastases (LM are not contraindicated if there are < 4 and they are easily resectable )[15]. Oncologic Results Results obtained with CCRS + HIPEC are interesting and promising. In the AFC study, overall 5-year survival was 27%. This result takes into account all the learning curves of 28 different centers and will be the worst possibly obtained. The results of experienced centers, concerning patients who underwent CCRS + HIPEC are consistent, with overall 5-year survival rates close to 40% [16-18]. It was 32% for the 70 patients reported on by da Silva et al.[17], 43% for the 59 patients reported by Verwaal et al. [16], and 48% for the 30 patients in the study by Elias et al.[18]. Such a survival rate has never been published before about PC, even if it concerns only selected patients. It is thus a real therapeutic revolution. Furthermore, these results are exactly similar to those obtained with hepatectomy for liver metastases [13]. The message appears to be that selected patients with PC should be treated with this combined therapy in the same way as selected patients with LM should be treated with hepatectomy, given that the same survival rates are obtained [19]. Post-operative mortality and morbidity The first studies concerning CCRS and HIPEC reported high post-operative mortality and morbidity rates, creating a obstacle to its diffusion. However, in the AFC study, the postoperative mortality rate was comparable to that of standard colorectal surgery (3%) and grade 3 or 4 complications (according to the National Cancer Institute Common Toxicity Criteria) occurred in 31% of the patients [13]. Titre 6
9 These acceptable operative results were confirmed in a recent Australian study, which reported a postoperative mortality rate of 3% and a severe morbidity rate of 43% [20]. Thus, fear of a severe post-operative course is no longer an acceptable reason for not using CCRS and HIPEC. Prognostic factors Some studies recently underlined the prognostic impact of the extent of the peritoneal disease (measured with the peritoneal cancer index : PCI) [14, 17]. This index ranges from 1 to 39 (a score from 0 to 3 is given for each of the 13 intraabdominal areas)[21]. Among the 523 patients in the AFC registry, a peritoneal index > 20 appeared as one of the main prognostic factors for survival in the multivariate analysis [14]. The results of the AFC registry are reported in figure 4. Five-year overall survival is directly correlated with the PCI, ranging from 44% with a very low PCI (less than 6) to 7% with the highest PCI (more than 19). We currently believe that a PCI exceeding 20 should be considered as a relative contraindication for CCRS with HIPEC. The main prognostic factors for survival selected by various studies through multivariate analysis are as follows : the completeness of cytoreductive surgery, a PCI score > 20, the presence of positive lymph nodes and the delivery of adjuvant chemotherapy[13, 17]. When they are resectable simultaneously with HIPEC, associated liver metastases merely exert a borderline non-significant impact [13]. Until now, no CCRS plus HIPEC technique has demonstrated clear superiority over another. The technique commonly used in our department has been extensively described elsewhere [22, 23]. Titre 7
10 4) New trends for HIPEC in the future Established macroscopic PC: a) Standardization of the techniques. A comparative study of the main techniques is desirable, but difficult and to perform and time-consuming. While awaiting the results of such a study, treatment decision-making is based on a consensus among experts. Ongoing multicentric studies are a way of standardizing these techniques. The relation between the duration and the temperature of HIPEC should be carefully explored. In addition, the intraperitoneal use of new targeted drugs ought to be explored. b) Progress with new targeting molecules. If new and more efficient molecules capable of treating colorectal cancers become available, then the place of HIPEC will be re-analyzed. A prospective multicentric trial will be necessary to compare CCRS and HIPEC to a non-surgical treatment using these new drugs. c) Cost-efficiency of CCRS-HIPEC. This combined treatment is complex and costly (approximately 35,000 Euros per patient). It cures only 20% of the patients with PC, but significantly increases median survival. Its cost-efficiency can be measured with the QALY method which measures the price of one year of survival gained with the treatment [24]. After that, each country will have to decide if it is rich enough to pay the price and whether treating this advanced disease is a priority or not. Also, The results of Titre 8
11 such treatment will have to be weighed against the cost of new systemic chemotherapy molecules (close to 5,000 Euros per month). d) A surgical procedure reserved for specialized centers. CCRS and HIPEC are technically challenging, with a rather long learning curve[13]. Moreover, as mentioned above, it is an expensive treatment. High volume and experienced centers obtain better results than others [13] and quality control measurement does not currently exist. Controlling the quality of surgery is currently difficult to implement and apply to gastric and rectal cancers. It will be even more difficult for this complex technique. This is why there is a strong rationale for authorizing this activity exclusively in a few specialized centers in the future. Prophylactic HIPEC for high-risk patients All the series concerning the treatment of established macroscopic PC conclude that survival results are far better when peritoneal disease is less bulky [13, 16, 17]. Also postoperative morbidity and mortality are significantly lower when the peritoneal index is lower, because surgery is less extensive [14,15]. These two points are strong arguments in favor of operating patients with the lowest peritoneal index. However, early PC is currently not detectable clinically, biologically or with imaging. Early PC is only detectable by a second-look laparotomy. Second-look laparoscopy is not recommended because it does not allow the surgeon to re-expose all the dissection planes of the first surgery, and because palpation cannot be used. The aim of this second-look procedure is to detect the beginning of PC early and to treat it with cytoreductive surgery plus HIPEC. As this a rather aggressive and expensive treatment, it should be proposed Titre 9
12 exclusively to patients presenting a high risk of developing PC after resection of the primary. A major proportion of the at-risk population has recently be defined by Elias et al [25] and concerns: 1) patients presenting a few nodules of synchronous PC which are completely resected with the primary tumor, 2) patients with ovarian metastasis, and 3) patients with a perforated primary tumor (spontaneous or iatrogenic). A second-look procedure performed one year after the first surgery and 6 months after the end of systemic adjuvant chemotherapy, in asymptomatic patients with a completely negative work-up, was able to detect macroscopic PC in respectively 63%, 75% and 33% of these sub-groups. Patients with macroscopic PC were treated with cytoreductive surgery plus HIPEC, with no mortality, low morbidity and a promising survival rate (2-year disease-free survival exceeding 50%). Patients without macroscopic PC were treated prophylactically with or without HIPEC. The subgroup receiving HIPEC presented far fewer peritoneal recurrences than those who did not receive HIPEC (17% versus 43%, respectively). Based on this preliminary study, a multicentric randomized trial was designed which will begin in France in All high-risk patients (see definition above) will receive the standard adjuvant systemic chemotherapy with FOLFOX over 6 months. Afterwards, a complete work-up will be performed. If it is negative, patients will be randomized between a simple survey (control group) and a second-look with in principle HIPEC. The main evaluation criterion will be the rate of peritoneal recurrences at 3 years. To date, the risk of developing PC has not been clearly established for patients with a pt4 lesion of the colon or an occlusive tumor. Data in the Titre 10
13 literature are discordant and a new prospective study on this issue would be useful. Conclusion In conclusion, comparable to the rise in the use of hepatectomy for colorectal LM observed fifteen years ago, CCRS and HIPEC is becoming the standard treatment for colorectal PC. This combined treatment is a complex and costly therapeutic package that is slowly being adopted by surgical teams. However, it is associated with promising long-term survival and is currently the only treatment able to cure patients with PC. Its future evolution may lead to even better oncologic and surgical results. The authors thank Ms lorna Saint-Ange for editing. Titre 11
14 Figure 1: Overall survival after surgery + HIPEC or standard systemic chemotherapy for peritoneal carcinomatosis (from Verwaal et al. J Clin Oncol 2003.) Titre 12
15 Figure 2: Overall survival after CCRS + HIPEC or standard systemic chemotherapy for peritoneal carcinomatosis (from Elias et al. J Clin Oncol 2009) Titre 13
16 Figure 3: Overall survival rate according to the completeness of cytoreductive surgery after surgery and HIPEC for peritoneal carcinomatosis (from Elias D et al. J Clin Oncol 2009) Titre 14
17 Figure 4: Overall survival rate according to the peritoneal cancer index after surgery and HIPEC for peritoneal carcinomatosis (from Elias D et al. J Clin Oncol 2009) Same Figures in black and white: figure 3 and figure 4 Titre 15
18 Titre 16
19 Titre 17
20 REFERENCES 1. Chu DZ, Lang NP, Thompson C, Osteen PK, Westbrook KC. Peritoneal carcinomatosis in nongynecologic malignancy. A prospective study of prognostic factors. Cancer 1989; 63: Sadeghi B, Arvieux C, Glehen O, Beaujard AC, Rivoire M, Baulieux J, et al. Peritoneal carcinomatosis from non-gynecologic malignancies: results of the EVOCAPE 1 multicentric prospective study. Cancer 2000; 88: Jayne DG, Fook S, Loi C, Seow-Choen F. Peritoneal carcinomatosis from colorectal cancer. Br J Surg 2002; 89: Spratt JS, Adcock RA, Muskovin M, Sherrill W, McKeown J. Clinical delivery system for intraperitoneal hyperthermic chemotherapy. Cancer Res 1980; 40: Sugarbaker PH, Cunliffe WJ, Beliveau JF, de Bruin E, Graves T. Rationale for perioperative intraperitoneal chemotherapy as a surgical adjuvant for gastrointestinal malignancy. Reg Cancer Treatment 1988; 1: Los G, Mutsaers PH, van der Vijgh WJ, Baldew GS, de Graaf PW, McVie JG. Direct diffusion of cis-diamminedichloroplatinum(ii) in intraperitoneal rat tumors after intraperitoneal chemotherapy: a comparison with systemic chemotherapy. Cancer Res 1989; 49: van de Vaart PJ, van der Vange N, Zoetmulder FA, van Goethem AR, van Tellingen O, ten Bokkel Huinink WW, et al. Intraperitoneal cisplatin with regional hyperthermia in advanced ovarian cancer: pharmacokinetics and cisplatin-dna adduct formation in patients and ovarian cancer cell lines. Eur J Cancer 1998; 34: Titre 18
21 8. Koga S, Hamazoe R, Maeta M, Shimizu N, Kanayama H, Osaki Y. Treatment of implanted peritoneal cancer in rats by continuous hyperthermic peritoneal perfusion in combination with an anticancer drug. Cancer Res 1984; 44: Elias D, Detroz B, Debaene B, Damia E, Leclercq B, Rougier P, et al. Treatment of peritoneal carcinomatosis by intraperitoneal chemohyperthermia: reliable and unreliable concepts. Hepatogastroenterology 1994; 41: Zoetmulder FA. Cancer cell seeding during abdominal surgery: experimental studies. Cancer Treat Res 1996; 82: Jacquet P, Elias D, Sugarbaker PH. [Tumor implantation in cicatrization sites following surgery for digestive cancers]. J Chir (Paris) 1996; 133: Verwaal VJ, van Ruth S, de Bree E, van Sloothen GW, van Tinteren H, Boot H, et al. Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J Clin Oncol 2003; 21: Elias D, Lefevre JH, Chevalier J, Brouquet A, Marchal F, Classe JM, et al. Complete cytoreductive surgery plus intraperitoneal chemohyperthermia with oxaliplatin for peritoneal carcinomatosis of colorectal origin. J Clin Oncol 2009; 27: Elias D, Gilly F, Boutitie F, Quenet F, Bereder JM, Mansvelt B, et al. Peritoneal Colorectal Carcinomatosis Treated With Surgery and Titre 19
22 Perioperative Intraperitoneal Chemotherapy: Retrospective Analysis of 523 Patients From a Multicentric French Study. J Clin Oncol 2010: January. 15. Elias D, Benizri E, Pocard M, Ducreux M, Boige V, Lasser P. Treatment of synchronous peritoneal carcinomatosis and liver metastases from colorectal cancer. Eur J Surg Oncol 2006; 32: Verwaal VJ, van Ruth S, Witkamp A, Boot H, van Slooten G, Zoetmulder FA. Long-term survival of peritoneal carcinomatosis of colorectal origin. Ann Surg Oncol 2005; 12: da Silva RG, Sugarbaker PH. Analysis of prognostic factors in seventy patients having a complete cytoreduction plus perioperative intraperitoneal chemotherapy for carcinomatosis from colorectal cancer. J Am Coll Surg 2006; 203: Elias D, Raynard B, Farkhondeh F, Goere D, Rouquie D, Ciuchendea R, et al. Peritoneal carcinomatosis of colorectal origin. Gastroenterol Clin Biol 2006; 30: Elias DM. Peritoneal carcinomatosis or liver metastases from colorectal cancer: similar standards for a curative surgery? Ann Surg Oncol 2004; 11: Chua TC, Saxena A, Schellekens JF, Liauw W, Yan TD, Fransi S, et al. Morbidity and Mortality Outcomes of Cytoreductive Surgery and Perioperative Intraperitoneal Chemotherapy at a Single Tertiary Institution: Towards a New Perspective of This Treatment. Ann Surg 2010; 251: Sugarbaker PH. Intraperitoneal chemotherapy and cytoreductive surgery for the prevention and treatment of peritoneal carcinomatosis and sarcomatosis. Semin Surg Oncol 1998; 14: Titre 20
23 22. Sugarbaker PH. Peritonectomy procedures. Ann Surg 1995; 221: Elias D, Sideris L, Baton O, Lasser P, Pocard M (2004) Traitement chirurgical a viseé curatrice des carcinoses peŕitoneáles. In: EMC Techniques chirurgicales - Appareil Digestif Bonastre J, De Baere T, Elias D, Evrard S, Rouanet P, Bazin C, et al. Cost of radiofrequency ablation in the treatment of hepatic malignancies. Gastroenterol Clin Biol 2007; 31: Elias D, Goere D, Di Pietrantonio D, Boige V, Malka D, Kohneh-Shahri N, et al. Results of systematic second-look surgery in patients at high risk of developing colorectal peritoneal carcinomatosis. Ann Surg 2008; 247: Titre 21
J Clin Oncol 28: by American Society of Clinical Oncology INTRODUCTION
VOLUME 28 NUMBER 1 JANUARY 1 2010 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T Peritoneal Colorectal Carcinomatosis Treated With Surgery and Perioperative Intraperitoneal Chemotherapy: Retrospective
More informationPeritoneal carcinomatosis (PC) arising from gastrointestinal cancer
71 Curative Treatment of Peritoneal Carcinomatosis Arising from Colorectal Cancer by Complete Resection and Intraperitoneal Chemotherapy D. Elias, M.D. F. Blot, M.D. A. El Otmany, M.D. S. Antoun, M.D.
More informationPseudomyxoma peritonei: a French multicentric study of 301 patients treated with cytoreductive surgery and intraperitoneal chemotherapy
Pseudomyxoma peritonei: a French multicentric study of 301 patients treated with cytoreductive surgery and intraperitoneal chemotherapy D. Elias, F. Gilly, F. Quenet, Jm. Bereder, L. Sideris, B. Mansvelt,
More informationMedical Policy An Independent Licensee of the Blue Cross and Blue Shield Association
Cytoreduction and Hyperthermic Page 1 of 10 Medical Policy An Independent Licensee of the Blue Cross and Blue Shield Association Title: Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy for the
More informationTREATMENT OF PERITONEAL COLORECTAL CARCINOMATOSIS
TREATMENT OF PERITONEAL COLORECTAL CARCINOMATOSIS Anna Lepistö, MD, PhD Department of Colorectal Surgery, Abdominal Center, Helsinki University Hospital Incidence, prevalence and risk factors for peritoneal
More informationResults of a French Multicentric Analysis
Peritonectomy, Perioperative and Intraoperative Intraperitoneal Chemotherapy for Carcinosis Arising from Gastric Cancer Results of a French Multicentric Analysis 17 th -19 th 2008 Report Digestive and
More informationResults of CRS and HIPEC in. Colorectal PSM. and. Pseudomyxoma Peritonei
Results of CRS and HIPEC in Colorectal PSM and Pseudomyxoma Peritonei K. Van der Speeten 05/10/12 Introduction Results Morbidity & Mortality Adjuvant HIPEC Conclusions K. Van der Speeten Introduction PSM
More informationRegional Therapy for Management of Peritoneal Carcinomatosis from Gastrointestinal Malignancies
Regional Therapy for Management of Peritoneal Carcinomatosis from Gastrointestinal Malignancies Byrne Lee, MD FACS Chief, Mixed Tumor Surgery Service City of Hope Division of Surgical Oncology September
More informationRegional Therapy for Management of Peritoneal Carcinomatosis from Gastrointestinal Malignancies
Regional Therapy for Management of Peritoneal Carcinomatosis from Gastrointestinal Malignancies Byrne Lee, MD FACS Chief, Mixed Tumor Surgery Service City of Hope Division of Surgical Oncology September
More informationPatient Presentation. 32 y.o. female complains of lower abdominal mass CEA = 433, CA125 = 201
Patient Presentation 32 y.o. female complains of lower abdominal mass CEA = 433, CA125 = 201 CT shows: Thickening of the right hemidiaphragm CT shows: Fluid in the right paracolic sulcus CT shows: Large
More informationCytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) for colorectal and appendiceal carcinomas with peritoneal carcinomatosis
JBUON 2017; 22(6): 1547-1553 ISSN: 1107-0625, online ISSN: 2241-6293 www.jbuon.com E-mail: editorial_office@jbuon.com ORIGINAL ARTICLE Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy
More informationDepartment of Surgery, Kusatsu General Hospital, Yabase Kusatsu 1660, Japan 2
Gastroenterology Research and Practice Volume 2012, Article ID 836425, 5 pages doi:10.1155/2012/836425 Clinical Study Morbidity and Mortality Outcomes of Cytoreductive Surgery and Hyperthermic Intraperitoneal
More informationJ Clin Oncol 22: by American Society of Clinical Oncology INTRODUCTION
VOLUME 22 NUMBER 16 AUGUST 15 2004 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T Cytoreductive Surgery Combined With Perioperative Intraperitoneal Chemotherapy for the Management of Peritoneal
More informationHow to deal with patients with isolated peritoneal metastases
ESMO Preceptorship Programme Colorectal Valencia 18-19 May 2018 Michel DUCREUX, MD, PhD Gustave Roussy Cancer Centre, Grand Paris, FRANCE How to deal with patients with isolated peritoneal metastases DISCLOSURE
More informationCytoreductive Strategies in the Treatment of Carcinomatosis of Colorectal Origin: Results of a Transdisciplinary National Survey
Send Orders for Reprints to reprints@benthamscience.net The Open Surgical Oncology Journal, 2013, 4, 1-6 1 Open Access Cytoreductive Strategies in the Treatment of Carcinomatosis of Colorectal Origin:
More informationVic J. Verwaal, MD, PhD, 1 Sjoerd Bruin, MD, 1 Henk Boot, MD, PhD, 2 Gooike van Slooten, MD, 1 and Harm van Tinteren, ScM 3
Annals of Surgical Oncology 15(9):2426 2432 DOI: 10.1245/s10434-008-9966-2 8-Year Follow-up of Randomized Trial: Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy Versus Systemic Chemotherapy
More informationCURRICULUM VITAE 2005
CURRICULUM VITAE 2005 Last Name : GLEHEN Fist Name: Olivier Current Address Department of Surgical Oncology University Hospital of LYON-SUD 69695 Pierre Bénite, France e-mail : olivier.glehen@chu-lyon.fr
More informationPlanned relaparotomy following curative resection of a locally advanced gastrointestinal cancer
Planned relaparotomy following curative resection of a locally advanced gastrointestinal cancer PD Dr. med. Michel Adamina, MSc Department of Surgery Agenda Prerequisite for successful CRS HIPEC Planned
More informationCytoreductive surgery and perioperative intraperitoneal chemotherapy for Rare Peritoneal Disease. Results of the French multicentric database
Cytoreductive surgery and perioperative intraperitoneal chemotherapy for Rare Peritoneal Disease Results of the French multicentric database Université Lyon 1 Centre Hospitalo-Universitaire Lyon-Sud EA
More informationThis is a submitted version of a paper published in European Journal of Surgical Oncology. Access to the published version may require subscription.
Uppsala University This is a submitted version of a paper published in European Journal of Surgical Oncology. Citation for the published paper: Cashin, P., Graf, W., Nygren, P., Mahteme, H. (2012) "Cytoreductive
More informationClinical Policy: Intraperitoneal Hyperthermic Chemotherapy for Abdominopelvic Cancers Reference Number: CP.MP. 346
Clinical Policy: Intraperitoneal Hyperthermic Chemotherapy for Abdominopelvic Reference Number: CP.MP. 346 Effective Date: 11/15 Last Review Date: 11/17 See Important Reminder at the end of this policy
More informationHIPEC treatment of peritoneal carcinomatosis in colorectal and gastric cancer Braam, Hidde
UvA-DARE (Digital Academic Repository) HIPEC treatment of peritoneal carcinomatosis in colorectal and gastric cancer Braam, Hidde Link to publication Citation for published version (APA): Braam, H. J.
More informationCOLON CANCER PERITONEAL CARCINOMATOSIS TREATMENT Prof. Annibale Donini
UNIVERSITY OF PERUGIA Department of General and Emergency Surgery Chief: Prof. Annibale Donini COLON CANCER PERITONEAL CARCINOMATOSIS TREATMENT Prof. Annibale Donini COLON CANCER IS A HIGHLY FREQUENT NEOPLASIA
More informationPOLICIES AND PROCEDURE MANUAL
POLICIES AND PROCEDURE MANUAL Policy: MP278 Section: Medical Benefit Policy Subject: Hyperthermia in Cancer Therapy (e.g., HIPEC) I. Policy: Hyperthermia in Cancer Therapy (e.g., HIPEC) II. Purpose/Objective:
More informationCytoreduction and HIPEC in The Netherlands: Nationwide Long-term Outcome Following the Dutch Protocol
Ann Surg Oncol (2013) 20:4224 4230 DOI 10.1245/s10434-013-3145-9 ORIGINAL ARTICLE GASTROINTESTINAL ONCOLOGY Cytoreduction and HIPEC in The Netherlands: Nationwide Long-term Outcome Following the Dutch
More informationSurgical Oncology, Mercy Medical Center, Baltimore, MD
Ann Surg Oncol (2012) 19:110 114 DOI 10.1245/s10434-011-1840-y ORIGINAL ARTICLE GASTROINTESTINAL ONCOLOGY The Role of Cytoreductive Surgery and Heated Intraperitoneal Chemotherapy (CRS/HIPEC) in Patients
More informationPeritoneal metastases of colorectal origin treated by cytoreduction and HIPEC: An overview
Submit a Manuscript: http://www.wjgnet.com/esps/ Help Desk: http://www.wjgnet.com/esps/helpdesk.aspx DOI: 10.4251/wjgo.v6.i10.407 World J Gastrointest Oncol 2014 October 15; 6(10): 407-412 ISSN 1948-5204
More informationUsing Pharmacologic Data to Plan Clinical Treatments for Patients with Peritoneal Surface Malignancy
72 Current Drug Discovery Technologies, 2009, 6, 72-81 Using Pharmacologic Data to Plan Clinical Treatments for Patients with Peritoneal Surface Malignancy Kurt Van der Speeten 1, Oswald Anthony Stuart
More informationFrom universal postoperative pain recommendations to procedure-specific pain management
From universal postoperative pain recommendations to procedure-specific pain management Hélène Beloeil, Francis Bonnet To cite this version: Hélène Beloeil, Francis Bonnet. From universal postoperative
More informationA model for calculation of growth and feed intake in broiler chickens on the basis of feed composition and genetic features of broilers
A model for calculation of growth and feed intake in broiler chickens on the basis of feed composition and genetic features of broilers Bernard Carré To cite this version: Bernard Carré. A model for calculation
More informationINTRAOPERATIVE HYPERTHERMIC INTRAPERITONEAL CHEMOTHERAPY (HIPEC)
UnitedHealthcare Commercial Medical Policy INTRAOPERATIVE HYPERTHERMIC INTRAPERITONEAL CHEMOTHERAPY (HIPEC) Policy Number: SUR052 Effective Date: January 1, 2019 Table of Contents Page INSTRUCTIONS FOR
More informationHIPEC Controversies in the Indications and Application of Regional Chemotherapy for Peritoneal Surface Malignancies
HIPEC Controversies in the Indications and Application of Regional Chemotherapy for Peritoneal Surface Malignancies Crescent City Cancer Update: GI and HPB Saturday September 24, 2016 George M. Fuhrman,
More informationCRS e HIPEC: Efficacia e Limiti
CRS e HIPEC: Efficacia e Limiti Marcello Deraco M.D. Responsabile Tumori Peritoneali The Concept of Cytoreductive Surgery Means a complete removal of all macroscopic tumor in the peritoneal cavity; It
More informationVirtual imaging for teaching cardiac embryology.
Virtual imaging for teaching cardiac embryology. Jean-Marc Schleich, Jean-Louis Dillenseger To cite this version: Jean-Marc Schleich, Jean-Louis Dillenseger. Virtual imaging for teaching cardiac embryology..
More informationRepeated cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with recurrent peritoneal carcinomatosis
Vassos et al. World Journal of Surgical Oncology (2016) 14:42 DOI 10.1186/s12957-016-0804-x RESEARCH Repeated cytoreductive surgery (CRS) with hyperthermic intraperitoneal (HIPEC) in patients with recurrent
More informationEfficacy of Vaccination against HPV infections to prevent cervical cancer in France
Efficacy of Vaccination against HPV infections to prevent cervical cancer in France Laureen Ribassin-Majed, Catherine Hill, Rachid Lounes To cite this version: Laureen Ribassin-Majed, Catherine Hill, Rachid
More informationHIPEC treatment of peritoneal carcinomatosis in colorectal and gastric cancer Braam, Hidde
UvA-DARE (Digital Academic Repository) HIPEC treatment of peritoneal carcinomatosis in colorectal and gastric cancer Braam, Hidde Link to publication Citation for published version (APA): Braam, H. J.
More informationRationale for the treatment. Peritoneal Surface Malignancy
Rationale for the treatment of Peritoneal Surface Malignancy K. Van der Speeten 05/10/12 A full circle :acknowledgements Rationale for the treatment of Peritoneal Surface Malignancy K. Van der Speeten
More informationMathieu Hatt, Dimitris Visvikis. To cite this version: HAL Id: inserm
Defining radiotherapy target volumes using 18F-fluoro-deoxy-glucose positron emission tomography/computed tomography: still a Pandora s box?: in regard to Devic et al. (Int J Radiat Oncol Biol Phys 2010).
More informationAvailable online at EJSO 37 (2011) 148e154. Accepted 26 October 2010 Available online 18 November 2010
Available online at www.sciencedirect.com EJSO 37 (2011) 148e154 www.ejso.com Prognostic factors and oncologic outcome in 146 patients with colorectal peritoneal carcinomatosis treated with cytoreductive
More informationPharmacokinetics of caspofungin in a critically ill patient with liver cirrhosis
Pharmacokinetics of caspofungin in a critically ill patient with liver cirrhosis Isabel Spriet, Wouter Meersseman, Pieter Annaert, Jan Hoon, Ludo Willems To cite this version: Isabel Spriet, Wouter Meersseman,
More informationBilateral anterior uveitis secondary to erlotinib
Bilateral anterior uveitis secondary to erlotinib Lik Thai Lim, Robert Alexander Blum, Chee Peng Cheng, Abdul Hanifudin To cite this version: Lik Thai Lim, Robert Alexander Blum, Chee Peng Cheng, Abdul
More informationTreatment of peritoneal metastases from colorectal cancer
Gastroenterology Report, 3(4), 2015, 298 302 doi: 10.1093/gastro/gov044 Advance Access Publication Date: 30 September 2015 Review REVIEW Treatment of peritoneal metastases from colorectal cancer Loreen
More informationCost-Effectiveness of Intraperitoneal Chemohyperthermia in the Treatment of Peritoneal Carcinomatosis from Colorectal Cancer
Volume 11 Number 3 2008 VALUE IN HEALTH Cost-Effectiveness of Intraperitoneal Chemohyperthermia in the Treatment of Peritoneal Carcinomatosis from Colorectal Cancer Julia Bonastre PhD 1 Julie Chevalier
More informationCRS and HIPEC for Colorectal Cancer. Rajesh Nair, MD UF Health Cancer Center-Orlando Health March 11, 2017
CRS and HIPEC for Colorectal Cancer Rajesh Nair, MD UF Health Cancer Center-Orlando Health March 11, 2017 Peritoneal Carcinomatosis from CRC Historically, a devastating problem Extreme morbidity from disease
More informationCytoreductive surgery and intraperitoneal chemotherapy for pseudomyxoma peritonei
Int J Colorectal Dis (2005) 20:155 160 DOI 10.1007/s00384-004-0648-7 O R I G I N A L A R T I C L E Z. Güner U. Schmidt M. H. Dahlke H. J. Schlitt J. Klempnauer P. Piso Cytoreductive surgery and intraperitoneal
More informationAscites and malnutrition are predictive factors for incomplete cytoreductive surgery for peritoneal carcinomatosis from gastric cancer
The American Journal of Surgery (2013) 205, 668-673 Clinical Surgery Ascites and malnutrition are predictive factors for incomplete cytoreductive surgery for peritoneal carcinomatosis from gastric cancer
More informationMP Cytoreductive Surgery and Perioperative Intraperitoneal Chemotherapy for Select Intra-Abdominal and Pelvic Malignancies
Medical Policy MP 2.03.07 Cytoreductive Surgery and Perioperative Intraperitoneal Chemotherapy for Select Intra-Abdominal and Pelvic BCBSA Ref. Policy: 2.03.07 Last Review: 07/25/2018 Effective Date: 07/25/2018
More informationIn vitro study of the effects of cadmium on the activation of the estrogen response element using the YES screen
In vitro study of the effects of cadmium on the activation of the estrogen response element using the YES screen Xavier Denier, Jérome Couteau, Magalie Baudrimont, Elisabeth M. Hill, Jeanette Rotchell,
More information1. Introduction. Correspondence should be addressed to Horacio N. López-Basave, Received 23 May 2011; Accepted 20 June 2011
International Scholarly Research Network ISRN Oncology Volume 2011, Article ID 526384, 6 pages doi:10.5402/2011/526384 Research Article Morbidity and Mortality of Cytoreductive Surgery with Hyperthermic
More informationThe Journal of Thoracic and Cardiovascular Surgery
Accepted Manuscript Mesothelioma: Live to Fight Another Day Andrea S. Wolf, MD, Raja M. Flores, MD PII: S0022-5223(17)32747-2 DOI: 10.1016/j.jtcvs.2017.11.060 Reference: YMTC 12301 To appear in: The Journal
More informationA Case Report of Surgical Resections with Local and Systemic Chemotherapy for Three Recurrences of Colon Cancer Occurring Ten Years after Colectomy
This is an Open Access article licensed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs 3.0 License (www.karger.com/oa-license), applicable to the online version of the article
More informationCRS and HIPEC for Peritoneal Carcinomatosis : An update and critical appraisal
CRS and HIPEC for Peritoneal Carcinomatosis : An update and critical appraisal K. Van der Speeten, MD, PhD Pretoria 08/10/16 2016 : the Good, the Bad and the Ugly Chemosurgery The surgery in chemosurgery
More informationMulti-template approaches for segmenting the hippocampus: the case of the SACHA software
Multi-template approaches for segmenting the hippocampus: the case of the SACHA software Ludovic Fillon, Olivier Colliot, Dominique Hasboun, Bruno Dubois, Didier Dormont, Louis Lemieux, Marie Chupin To
More informationPeritoneal dissemination is a common manifestation of disease
ORIGINAL ARTICLE Identification of a Subgroup of Patients at Highest Risk for Complications After Surgical Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy Dario Baratti, MD, Shigeki Kusamura,
More informationClinical Study Prevention of Peritoneal Metastases from Colon Cancer in High-Risk Patients: Preliminary Results of Surgery plus Prophylactic HIPEC
Gastroenterology Research and Practice Volume 2012, Article ID 141585, 7 pages doi:10.1155/2012/141585 Clinical Study Prevention of Peritoneal Metastases from Colon Cancer in High-Risk : Preliminary Results
More informationPrevalence and Management of Non-albicans Vaginal Candidiasis
Prevalence and Management of Non-albicans Vaginal Candidiasis Nalin Hetticarachchi, Ruth Ashbee, Janet D Wilson To cite this version: Nalin Hetticarachchi, Ruth Ashbee, Janet D Wilson. Prevalence and Management
More informationIncidence of brain metastases in HER2+ gastric or gastroesophageal junction adenocarcinoma.
Incidence of brain metastases in HER2+ gastric or gastroesophageal junction adenocarcinoma. Christophe Blay, Dan Cristian Chiforeanu, Eveline Boucher, Florian Cabillic, Romain Desgrippes, Bérengère Leconte,
More informationMATERIALS AND METHODS Patients
Yonago Acta Medica 2017;60:174 178 Original Article Gross Appearance and Curability Are Predictive Factors of a Better Prognosis After Gastrectomy in Gastric Cancer Patients with Metastasis to the Adjacent
More informationPRELIMINARY PROGRAM. 11 th International Workshop on Peritoneal Surface Malignancy SEPTEMBER 9-11,
11 th International Workshop on Peritoneal Surface Malignancy PRELIMINARY PROGRAM SEPTEMBER 9-11, 2018 Maison de la Chimie, Paris, France www.psogi2018.com 9THSATURDAY 8TH 2SUNDAY Saturday, September 8
More informationImproving HIV management in Sub-Saharan Africa: how much palliative care is needed?
Improving HIV management in Sub-Saharan Africa: how much palliative care is needed? Karilyn Collins, Richard Harding To cite this version: Karilyn Collins, Richard Harding. Improving HIV management in
More informationMP Hyperthermic Intraperitoneal Chemotherapy for Select IntraAbdominal and Pelvic Malignancies. Related Policies None
Medical Policy MP 2.03.07 BCBSA Ref. Policy: 2.03.07 Last Review: 10/18/2018 Effective Date: 01/25/2019 Section: Medicine Related Policies None DISCLAIMER Our medical policies are designed for informational
More informationVolume measurement by using super-resolution MRI: application to prostate volumetry
Volume measurement by using super-resolution MRI: application to prostate volumetry Estanislao Oubel, Hubert Beaumont, Antoine Iannessi To cite this version: Estanislao Oubel, Hubert Beaumont, Antoine
More informationIJC International Journal of Cancer
IJC International Journal of Cancer Peritoneal carcinomatosis of gastric origin: A population-based study on incidence, survival and risk factors Irene Thomassen 1,2, Yvette R. van Gestel 2, Bert van Ramshorst
More informationCorporate Medical Policy
Corporate Medical Policy Hyperthermic Intraperitoneal Chemotherapy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: hyperthermic_intraperitoneal_chemotherapy 5/19/2005 3/2018 3/2019
More informationKey words: appendiceal carcinoma; peritonectomy; intraperitoneal chemotherapy.
EJSO 2001; 27: 286 290 doi:10.1053/ejso.2000.1095, available online at http://www.idealibrary.com on Improved prognosis following peritonectomy procedures and hyperthermic intraperitoneal chemotherapy
More informationCurrent standard in treatment of peritoneal carcinomotisis. Data behind the HIPEC trials
Current standard in treatment of peritoneal carcinomotisis Data behind the HIPEC trials Overview Peritoneal carcinomatosis STANDARD treatment HIPEC Results of treatment Counter side of treatment Peritoneal
More informationPharmacologic rationale for treatments of peritoneal surface malignancy from colorectal cancer
Online Submissions: http://www.wjgnet.com/1948-5204office wjgo@wjgnet.com doi:10.4251/wjgo.v2.i1.19 World J Gastrointest Oncol 2010 January 15; 2(1): 19-30 ISSN 1948-5204 (online) 2010 Baishideng. All
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Cytoreductive Surgery and Perioperative Intraperitoneal Page 1 of 26 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Cytoreductive Surgery and Perioperative Intraperitoneal
More informationPERITONEAL CARCINOMATOSIS (PC) of colorectal origin
Randomized Trial of Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy Versus Systemic Chemotherapy and Palliative Surgery in Patients With Peritoneal Carcinomatosis of Colorectal Cancer By Vic
More informationAccepted Manuscript. Surgery for mesothelioma: less is more, more or less. Steven Milman, MD, Thomas Ng, MD
Accepted Manuscript Surgery for mesothelioma: less is more, more or less Steven Milman, MD, Thomas Ng, MD PII: S0022-5223(17)32706-X DOI: 10.1016/j.jtcvs.2017.11.029 Reference: YMTC 12266 To appear in:
More informationKathleen A. Cummins 1, Gregory B. Russell 2, Konstantinos I. Votanopoulos 1, Perry Shen 1, John H. Stewart 1, Edward A. Levine 1.
Original Article Peritoneal dissemination from high-grade appendiceal cancer treated with cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) Kathleen A. Cummins 1, Gregory
More informationManagement of Pseudomyxoma Peritonei (PMP) and Colon Cancer Carcinomatosis by Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy (HIPEC).
Surgical Oncology Department Management of Pseudomyxoma Peritonei (PMP) and Colon Cancer Carcinomatosis by Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy (HIPEC). 21/04/2010 THERMOMETRY 1000-1500
More informationCytoreductive Surgery and Perioperative Intraperitoneal Chemotherapy for Select Intra-Abdominal and Pelvic Malignancies
Last Review Status/Date: December 2016 Page: 1 of 29 Intraperitoneal Chemotherapy for Select Intra- Description Cytoreductive surgery (CRS) comprises peritonectomy (ie, peritoneal stripping) procedures
More informationOn the empirical status of the matching law : Comment on McDowell (2013)
On the empirical status of the matching law : Comment on McDowell (2013) Pier-Olivier Caron To cite this version: Pier-Olivier Caron. On the empirical status of the matching law : Comment on McDowell (2013):
More informationCytoreductive Surgery and Perioperative Intraperitoneal Chemotherapy for Select Intra-Abdominal and Pelvic Malignancies
Last Review Status/Date: March 2015 Page: 1 of 32 Intraperitoneal Chemotherapy for Select Intra- Description Pseudomyxoma peritonei describes extensive mucus accumulation within the peritoneum resulting
More informationF. Cavaliere, M. De Simone, S. Virzì, M. Deraco, C.R. Rossi, A. Garofalo, F. Di Filippo, D. Giannarelli, M. Vaira, M. Valle, et al.
Prognostic Factors and Oncologic Outcome in 146 Patients with Colorectal Peritoneal Carcinomatosis Treated with Cytoreductive Surgery Combined with Hyperthermic Intraperitoneal Chemotherapy: Italian Multicenter
More informationDietary acrylamide exposure among Finnish adults and children: The potential effect of reduction measures
Dietary acrylamide exposure among Finnish adults and children: The potential effect of reduction measures Tero Hirvonen, Marika Jestoi, Heli Tapanainen, Liisa Valsta, Suvi M Virtanen, Harri Sinkko, Carina
More informationHyperthermic Intraperitoneal Chemotherapy (HIPEC)
Medical Coverage Policy Effective Date...10/15/2017 Next Review Date...10/15/2018 Coverage Policy Number... 0396 Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Table of Contents Related Coverage Resources
More informationPseudomyxoma peritoni et al HOW TO TREAT PERITONEAL MALIGNANCIES
Pseudomyxoma peritoni et al HOW TO TREAT PERITONEAL MALIGNANCIES Case Presentation 72M 3 weeks abdominal distension and lower abdominal pain. 3 weeks constipation w/ 2-3 BM per week. Post-prandial epigastric/substernal
More informationClinicopathological features and prognosis of pseudomyxoma peritonei
EXPERIMENTAL AND THERAPEUTIC MEDICINE 7: 185-190, 2014 Clinicopathological features and prognosis of pseudomyxoma peritonei HUAN WANG 1*, XUEJUN WANG 2*, YANFANG JU 1, JINLIANG WANG 1, XIN ZHANG 1, YAO
More informationUrological Procedures in Patients with Peritoneal Carcinomatosis of Colorectal Cancer Treated with HIPEC: Morbidity and Survival Analysis
Urological Procedures in Patients with Peritoneal Carcinomatosis of Colorectal Cancer Treated with HIPEC: Morbidity and Survival Analysis HIDDE J. BRAAM 1, THIJS R. VAN OUDHEUSDEN 2, IGNACE H.J.T. DE HINGH
More informationDaily alternating deferasirox and deferiprone therapy for hard-to-chelate β-thalassemia major patients
Daily alternating deferasirox and deferiprone therapy for hard-to-chelate β-thalassemia major patients Manuela Balocco, Paola Carrara, Valeria Pinto, Gian Luca Forni To cite this version: Manuela Balocco,
More informationHepatobiliary Procedures in Patients Undergoing Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy
Ann Surg Oncol (2011) 18:1052 1059 DOI 10.1245/s10434-010-1415-3 ORIGINAL ARTICLE GASTROINTESTINAL ONCOLOGY Hepatobiliary Procedures in Patients Undergoing Cytoreductive Surgery and Hyperthermic Intraperitoneal
More informationOptimal drugs for HIPEC in different tumors
JBUON 2015; 20 (Suppl. 1): S40-S46 ISSN: 1107-0625, online ISSN: 2241-6293 www.jbuon.com E-mail: editorial_office@jbuon.com REVIEW ARTICLE Optimal drugs for HIPEC in different tumors Eelco de Bree Department
More informationNATIONAL INSTITUTE FOR CLINICAL EXCELLENCE
NATIONAL INSTITUTE FOR CLINICAL EXCELLENCE INTERVENTIONAL PROCEDURES PROGRAMME Interventional procedures overview of complete cytoreduction Introduction (Sugarbaker technique) for pseudomyxoma peritonei
More informationPurpose. Page 2 of 24
Accuracy of MDCT in the preoperative definition of peritoneal cancer index (PCI) in patients with advanced ovarian cancer who underwent peritonectomy and hyperthermic intraperitoneal chemotherapy (HIPEC)
More informationAccepted Manuscript. Preoperative CEA in Patients with Colorectal Metastases Matters. Benny Weksler, MBA, MD
Accepted Manuscript Preoperative CEA in Patients with Colorectal Metastases Matters Benny Weksler, MBA, MD PII: S0022-5223(19)30068-6 DOI: https://doi.org/10.1016/j.jtcvs.2019.01.016 Reference: YMTC 14019
More informationOptimal electrode diameter in relation to volume of the cochlea
Optimal electrode diameter in relation to volume of the cochlea Dan Gnansia, Thomas Demarcy, Clair Vandersteen, Charles Raffaelli, Nicolas Guevara, Hervé Delingette, Nicholas Ayache To cite this version:
More informationSurgical Management of Advanced Stage Colon Cancer. Nathan Huber, MD 6/11/14
Surgical Management of Advanced Stage Colon Cancer Nathan Huber, MD 6/11/14 Colon Cancer Overview Approximately 50,000 attributable deaths per year Colorectal cancer is the 3 rd most common cause of cancer-related
More informationClinical Study Adjuvant Perioperative Intraperitoneal Chemotherapy in Locally Advanced Colorectal Carcinoma: Preliminary Results
International Scholarly Research Network ISRN Surgery Volume 2011, Article ID 529876, 6 pages doi:10.5402/2011/529876 Clinical Study Adjuvant Perioperative Intraperitoneal Chemotherapy in Locally Advanced
More informationReview of a Personal Experience in the Management of Carcinomatosis and Sarcomatosis
Jpn J Clin Oncol 2001;31(12)573 583 Special Article Review of a Personal Experience in the Management of Carcinomatosis and Sarcomatosis Paul H. Sugarbaker Washington Cancer Institute, Washington, DC,
More informationIodide mumps: Sonographic appearance
Iodide mumps: Sonographic appearance Salvatore Greco, Riccardo Centenaro, Giuseppe Lavecchia, Francesco Rossi To cite this version: Salvatore Greco, Riccardo Centenaro, Giuseppe Lavecchia, Francesco Rossi.
More informationSurgical management and neoadjuvant chemotherapy for stage III-IV ovarian cancer
Ovarian cancer Surgical management and neoadjuvant chemotherapy for stage III-IV ovarian cancer JM. Classe, R. Rouzier, O.Glehen, P.Meeus, L.Gladieff, JM. Bereder, F Lécuru Suitable candidates for neo-adjuvant
More informationINTRAPERITONEAL CHEMOTHERAPY, CYTOREDUCTION
INTRAPERITONEAL CHEMOTHERAPY, CYTOREDUCTION Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures,
More informationEnrichment culture of CSF is of limited value in the diagnosis of neonatal meningitis
Enrichment culture of CSF is of limited value in the diagnosis of neonatal S. H. Chaudhry, D. Wagstaff, Anupam Gupta, I. C. Bowler, D. P. Webster To cite this version: S. H. Chaudhry, D. Wagstaff, Anupam
More informationIJC International Journal of Cancer
IJC International Journal of Cancer Predictors and survival of synchronous peritoneal of colorectal origin: a population-based study Valery E. Lemmens 1,2, Yvonne L. Klaver 3, Vic J. Verwaal 4, Harm J.
More informationThe association of and -related gastroduodenal diseases
The association of and -related gastroduodenal diseases N. R. Hussein To cite this version: N. R. Hussein. The association of and -related gastroduodenal diseases. European Journal of Clinical Microbiology
More informationManagement of Stage IV Colorectal Cancer: Expanding the Horizon
Management of Stage IV Colorectal Cancer: Expanding the Horizon May Tee, MD, MPH and Jan Franko, MD, PhD MercyOne Surgical Group (Mercy Surgical Affiliates) GI Oncology Conference 2019 March 1, 2019 Disclosures
More informationHepatobiliary and pancreatic procedures during cytoreductive surgery and HIPEC
JBUON 2017; 22(5): 1338-1344 ISSN: 1107-0625, online ISSN: 2241-6293 www.jbuon.com E-mail: editorial_office@jbuon.com ORIGINAL ARTICLE Hepatobiliary and pancreatic procedures during cytoreductive surgery
More information